Vesna D. Garovic1, Manuela Aschauer2, Thomas Kittner3, International Investigator team SOV301 Investigators4
1Nephrology, Mayo Clinic, Rochester, MN, USA; 2Universittsklinikum , Graz, Austria; 3Institut und Poliklinik fr Rntgendiagnostik, Dresden, Germany; 4International multicenter trial
In a multicenter, international, controlled study of Omniscan (gadodiamide)-enhanced MRA for evaluation of patients with suspected or known renal artery stenosis, renal function was assessed as part of overall safety monitoring. This report is to present potential acute effect of Omniscan administration on kidney function. Single dose administration of 0.1 mmol/kg Omniscan for contrast-enhanced MRA of renal arteries for detection of renal artery stenosis has minimal impact on patients kidney function. No difference was seen in contrast-induced nephrotoxicity or adverse event rates between patients with baseline GFR <60 and those 60 mL/min/1.73 m2.